Real‐world outcomes of FOLFIRINOX vs gemcitabine and nab‐paclitaxel in advanced pancreatic cancer: A population‐based propensity score‐weighted analysis

Real‐world outcomes of FOLFIRINOX vs gemcitabine and nab‐paclitaxel in advanced pancreatic cancer: A population‐based propensity score‐weighted analysis

Abstract Background In Ontario, FOLFIRINOX (FFX) and gemcitabine + nab‐paclitaxel (GnP) have been publicly funded for first‐line unresectable locally advanced pancreatic cancer (uLAPC) or metastatic pancreatic cancer (mPC) since April 2015. We examined the real‐world effectiveness and safety of FFX...

Full description

Bibliographic Details
Main Authors: Kelvin K. W. Chan, Helen Guo, Sierra Cheng, Jaclyn M. Beca, Ruby Redmond‐Misner, Wanrudee Isaranuwatchai, Lucy Qiao, Craig Earle, Scott R. Berry, James J. Biagi, Stephen Welch, Brandon M. Meyers, Nicole Mittmann, Natalie Coburn, Jessica Arias, Deborah Schwartz, Wei F. Dai, Scott Gavura, Robin McLeod, Erin D. Kennedy
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Cancer Medicine
Subjects:
FOLFIRINOX
gemcitabine
outcomes
pancreatic cancer
real‐world evidence
Online Access:https://doi.org/10.1002/cam4.2705

Internet

https://doi.org/10.1002/cam4.2705

Similar Items